1519TiP Japanese Society of Medical Oncology/Health Authority of the Japanese Government Cooperative Virtual Educational Program for Improving the Clinical Annotation for Cancer Genomic Medicine

Abstract

Comprehensive genomic profiling tests are approved for refractory cancer patients in Japan with the condition that all tests be annotated by a molecular tumor board (MTB), at 12 core and 33 hub government-designated hospitals. Our study assessing the MTB performance of all core hospitals using 50 simulated cases indicated that sharing information on available matched therapies, particularly for genomic alterations with low evidence levels by the Japanese classification (PMID: 33249514), is needed to improve the quality of recommendations by MTBs (Kage H, et al #1097 ESMO 2021).